| |
| |
|
| Insider
Information: |
Burow Kristina |
| Relationship: |
Director, 10% Owner |
| City: |
Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
45,023 |
|
|
Indirect Shares
|
42,338,477 |
|
|
| Direct
Value |
$581,620 |
|
|
|
Indirect Value
|
$358,536,201 |
|
|
| Total
Shares |
42,383,500 |
|
|
| Total
Value |
$359,117,821 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
15
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
15
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-15.0
|
0.0
|
| Percentage
Gain/Loss : |
 -16.7%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Receptos, Inc. |
RCPT |
Director |
2015-08-27 |
0 |
2015-08-25 |
0 |
Premium* |
|
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
Director |
2017-08-01 |
0 |
2019-02-22 |
1,865,800 |
Premium* |
|
|
Unity Biotechnology Inc |
UBX |
Director |
2018-05-07 |
0 |
2018-05-07 |
1,795,411 |
Premium* |
|
|
Scholar Rock Holding Corp |
SRRK |
Director |
2023-12-21 |
5,339 |
2023-12-21 |
2,345,711 |
Premium* |
|
|
Gossamer Bio Inc |
GOSS |
Director |
2019-02-12 |
0 |
2019-02-12 |
4,027,958 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director |
|
0 |
2019-10-16 |
1,000,000 |
Premium* |
|
|
Beam Therapeutics Inc. |
BEAM |
Director |
2021-06-30 |
12,067 |
2021-06-30 |
2,921,519 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
Director |
2020-09-18 |
0 |
2020-09-18 |
158,734 |
Premium* |
|
|
Neumora Therapeutics, Inc. |
NMRA |
Director, 10% Owner |
2023-12-08 |
27,617 |
2023-12-08 |
28,223,344 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
68 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,243,039 |
4,121,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,921,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,012 |
2,012 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
4,023 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,721,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
6,034 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-03-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,521,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
8,045 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,321,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
10,056 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,121,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
2,921,519 |
0 |
- |
|
| BEAM |
Beam Therapeutics Inc. |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
12,067 |
0 |
- |
|
| GOSS |
Gossamer Bio Inc |
Director |
– • – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
8,055,916 |
4,027,958 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
Director |
– • – |
2020-09-18 |
4 |
B |
$13.00 |
$2,990,000 |
I/I |
230,000 |
158,734 |
2.1 |
- |
|
| MTCR |
Metacrine, Inc. |
Director |
– • – |
2020-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,710,503 |
138,734 |
0 |
- |
|
| NMRA |
Neumora Therapeutics, Inc... |
|
• • • |
2023-09-19 |
4 |
B |
$17.00 |
$25,500,000 |
I/I |
1,500,000 |
3,624,143 |
0.01 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
|
• • • |
2023-09-19 |
4 |
A |
$0.00 |
$0 |
I/I |
17,424,704 |
2,124,143 |
0 |
- |
|
| NMRA |
Neumora Therapeutics, Inc... |
|
• • • |
2023-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
13,620 |
13,620 |
0 |
- |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-22 |
4 |
B |
$11.14 |
$445,600 |
I/I |
40,000 |
3,664,143 |
2.25 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-25 |
4 |
B |
$10.80 |
$681,464 |
I/I |
60,740 |
3,724,883 |
2.25 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-26 |
4 |
B |
$11.73 |
$398,820 |
I/I |
34,000 |
3,758,883 |
2.25 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-27 |
4 |
B |
$12.31 |
$301,644 |
I/I |
24,504 |
3,783,387 |
2.25 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-28 |
4 |
B |
$13.06 |
$563,699 |
I/I |
41,951 |
3,825,338 |
2.25 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
Director |
– • • |
2023-09-29 |
4 |
B |
$13.98 |
$483,149 |
I/I |
34,560 |
3,859,898 |
2.25 |
% |
|
68 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
